Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AventaMed Ltd.

Office-based, one-shot tympanostomy tube placement

This article was originally published in Start Up

Executive Summary

More than 2.2 million cases of otitis media with effusion are diagnosed each year worldwide, with as many as 90% of children having at least one episode by age 10. The standard treatment is surgical placement of tiny tympanostomy tubes to ventilate the middle ear space, but AventaMed Ltd. is working to dramatically reduce costs in treating OME and to improve the patient experience with a novel device for tympanostomy tube placement that takes less than one second in an office setting.

You may also be interested in...



The Long And Short Of Accelerated Approval Accountability In US

The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.

Two Korean Pharmas Vie For Wins In High-Need Gout Space

Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.

US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel